Here’s Why RGAIA Considers Maravai LifeSciences Holdings’ (MRVI) Margin Structure as the Best

RGA Investment Advisors, an investment management company released its first quarter 2024 investor letter. A copy of the letter can be downloaded here. Strong economic growth combined with frustratingly resilient inflation defined the macroeconomic environment in the first quarter. The large caps outperformed their smaller counterparts in Q1. It may be the result of continued momentum in the market. Kindly check the top 5 stocks of the strategy to know its best picks in 2024.

RGA Investment Advisors highlighted stocks like Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), in the first quarter 2024 investor letter. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is a life sciences company. The one-month return of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was -33.69%, and its shares lost 45.43% of their value over the last 52 weeks. On June 14, 2024, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) stock closed at $7.52 per share with a market capitalization of $1.894 billion.

RGA Investment Advisors stated the following regarding Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) in its first quarter 2024 investor letter:

“We first purchased shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) early in Q3 of 2023. Much like our experience with META in 2022, almost immediately following our first purchases, the stock’s price tumbled. Given Maravai is a small cap, with a fairly illiquid float and volatile shares, we started our position on the smaller side. As the stock continued to stay weak, we used this as an opportunity to meaningfully increase our holding, much as we had done with META.

Maravai first hit public markets in late 2020 on the heels of its phenomenal success in helping the Pfizer/BioN-Tech mRNA vaccine approach commercial launch. Maravai was formed as a holding company backed by private equity firm GTCR. Its two key subsidiaries are TriLink Biotechnologies and Cygnus Technologies, in the Nucleic Acid Production (NAP) and Biologics Safety Testing (BST) segments respectively. TriLink is the subsidiary whose capabilities formed a critical piece of the Pfizer/BioNTech vaccine, while Cygnus is one of the most important quality control companies for the manufacturing of biologics. Each is an incredibly unique asset…” (Click here to read the full text)

A researcher in a laboratory coat working with laboratory equipment for nucleic acids.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 25 hedge fund portfolios held Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) at the end of the first quarter which was 26 in the previous quarter. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) reported $64 million in revenues in the first quarter, $8 million in total adjusted EBITDA, and a loss of $0.02 in adjusted fully diluted EPS. While we acknowledge the potential of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

In another article, we discussed Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) and shared ClearBridge Mid Cap Strategy’s views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q1 2024 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.